PEG-uricase as therapy for refractory gout

Hershfield, Michael S.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: Food and Drug Administration (FDA)
• Type: Research Project (R01)
• Project #: 5R01FD002537-03
• Application #: 7410031
• Study Section: Special Emphasis Panel (ZFD1-SRC (99))
• Program Officer: Ganti, Usha
• Project Start: 2004-06-01
• Project End: 2009-05-31
• Budget Start: 2006-06-01
• Budget End: 2009-05-31
• Support Year: 3
• Fiscal Year: 2006

Institution

• Name: Duke University
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 044387793
• City: Durham
• State: NC
• Country: United States
• Zip Code: 27705

Publications

Hershfield, Michael S; Ganson, Nancy J; Kelly, Susan J et al. (2014) Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther 16:R63

Hershfield, Michael S; Roberts 2nd, L Jackson; Ganson, Nancy J et al. (2010) Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci U S A 107:14351-6